Anti-folate receptor-α IgE but not IgG recruits macrophages to attack tumors via TNFa/MCP-1 signaling

Cancer Research

Volumn 77, Issue 5, 2017, Pages 1127-1141

  Josephs, Debra H ^a,b   Bax, Heather J ^a,b,c   Dodev, Tihomir ^b,c,d   Georgouli, Mirella ^c   Nakamura, Mano ^a   Pellizzari, Giulia ^a,c   Saul, Louise ^a,b,c   Karagiannis, Panagiotis ^a,b   Cheung, Anthony ^a,c   Herraiz, Cecilia ^c   Ilieva, Kristina M ^a,b,c   Correa, Isabel ^a,b   Fittall, Matthew ^a,b,c   Crescioli, Silvia ^a,b   Gazinska, Patrycja ^e   Woodman, Natalie ^e   Mele, Silvia ^a   Chiaruttini, Giulia ^a   Gilbert, Amy E ^a,b   Koers, Alexander ^d   Bracher, Marguerite ^c   Selkirk, Christopher ^f   Lentfer, Heike ^f   Barton, Claire ^f   Lever, Elliott ^a   Muirhead, Gareth ^d   Tsoka, Sophia ^d   Canevari, Silvana ^g   Figini, Mariangela ^g   Montes, Ana ^b   Downes, Noel ^h   Dombrowicz, David ⁱ   Corrigan, Christopher J ^d   Beavil, Andrew J ^b,c,d   Nestle, Frank O ^a,b,j   Jones, Paul S ^f   Gould, Hannah J ^b,c,d   Sanz Moreno, Victoria ^c   Blower, Philip J ^d   Spicer, James F ^c   Karagiannis, Sophia N ^a,b,c   more..

^a GUY S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h SK10 4TJ   (United Kingdom)

ⁱ INSERM   (France)

^j Inflammation and Immunology Research Unit   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; FOLATE RECEPTOR 1; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; ANTI-IGE ANTIBODIES; ANTIIDIOTYPIC ANTIBODY; TNF PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LUNG METASTASIS; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; OVARY CANCER; RAT; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; IMMUNOLOGY; OVARIAN NEOPLASMS; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CELL LINE, TUMOR; FEMALE; FOLATE RECEPTOR 1; HUMANS; MACROPHAGES; OVARIAN NEOPLASMS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85015827591     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1829     Document Type: Article

References (50)

1. Woof JM. Insights from Fc receptor biology: a route to improved antibody reagents. MAbs 2012;4:291-3.
2. Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 2015;112:6140-5.
3. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 2015;15:361-70.
4. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009;8:226-34.
5. White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015;27:138-48.
6. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003;21:579-628.
7. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007;7:365-78.
8. Jensen-Jarolim E, Pawelec G. The nascent field of AllergoOncology. Cancer Immunol Immunother 2012;61:1355-7.
9. Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE immunotherapy: a novel concept with promise for the treatmentof cancer. MAbs 2014;6:54-72.
10. Nigro EA, Soprana E, Brini AT, Ambrosi A, Yenagi VA, Dombrowicz D, et al. An antitumor cellular vaccine based on a mini-membrane IgE. J Immunol 2012;188:103-10.
11. Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, et al. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res 2007;67:3406-11.
12. Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, et al. IgE/FceRI-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses. Cell Rep 2015;10:1487-95.
13. Bax HJ, Josephs DH, Pellizzari G, Spicer JF, Montes A, Karagiannis SN. Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs 2016;8:1437-55.
14. Wulaningsih W, Holmberg L, Garmo H, Karagiannis SN, Ahlstedt S, Malmstrom H, et al. Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. Oncoimmunology 2016;5: e1154250.
15. Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget 2016; 7:52553-74.
16. Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 2015;26:2034-43.
17. Quarta A, Bernareggi D, Benigni F, Luison E, Nano G, Nitti S, et al. Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparti-cles: a full study to provide the proof of principle from in vitro to in vivo. Nanoscale 2015;7:2336-51.
18. Gould HJ, Mackay GA, Karagiannis SN, O'Toole CM, Marsh PJ, Daniel BE, et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999;29:3527-37.
19. Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003;33:1030-40.
20. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007;179:2832-43.
21. Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother 2012;61:1547-64.
22. Josephs DH, Bax HJ, Karagiannis SN. Tumour-associated macrophage polarisation and re-education with immunotherapy. Front Biosci 2015;7:293-308.
23. Gounni AS, Lamkhioued B, Ochiai K, Tanaka Y, Delaporte E, Capron A, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994;367:183-6.
24. Capron M, Capron A. Immunoglobulin E and effector cells in schistoso-miasis. Science 1994;264:1876-7.
25. Vouldoukis I, Mazier D, Moynet D, Thiolat D, Malvy D, Mossalayi MD. IgE mediates killing of intracellular Toxoplasma gondii by human macro-phages through CD23-dependent, interleukin-10 sensitive pathway. PLoS One 2011;6:e18289.
26. Dombrowicz D, Quatannens B, Papin JP, Capron A, Capron M. Expression of a functional Fc epsilon RI on rat eosinophils and macrophages. J Immunol 2000;165:1266-71.
27. Marquet RL, Westbroek DL, Jeekel J. Interferon treatment of a transplant-able rat colon adenocarcinoma: importance of tumor site. Int J Cancer 1984;33:689-92.
28. Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991; 51:6125-32.
29. Bottero F, Tomassetti A, Canevari S, Miotti S, Menard S, Colnaghi MI. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 1993;53:5791-6.
30. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985;45:4970-9.
31. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012;19:197-208.
32. Greer AM, Wu N, Putnam AL, Woodruff PG, Wolters P, Kinet JP, et al. Serum IgE clearance is facilitated by human FcepsilonRI internalization. J Clin Invest 2014;124:1187-98.
33. Holladay C, Power K, Sefton M, O'Brien T, Gallagher WM, Pandit A. Functionalized scaffold-mediated interleukin 10 gene delivery signifi-cantly improves survival rates of stem cells in vivo. Mol Ther 2011; 19:969-78.
34. Dodev TS, Karagiannis P, Gilbert AE, Josephs DH, Bowen H, James LK, et al. A tool kit for rapid cloning and expression of recombinant antibodies. Sci Rep 2014;4:5885.
35. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.Cancer Immunol Immunother 2009;58:915-30.
36. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-65.
37. Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010; 10:220.
38. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005; 23:8959-67.
39. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60:5857-61.
40. Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 2002;140:320-8.
41. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Ostling J, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep 2016; 15:2000-11.
42. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013;123:1457-74.
43. Karagiannis P, Gilbert AE, Nestle FO, Karagiannis SN. IgG4 antibodies and cancer-associated inflammation: insights into a novel mechanism of immune escape. Oncoimmunology 2013;2:e24889.
44. Saul L, Ilieva KM, Bax HJ, Karagiannis P, Correa I, Rodriguez-Hernandez I, et al. IgG subclassswitching and clonal expansion incutaneous melanoma and normal skin. Sci Rep 2016;6:29736.
45. Karagiannis P, Villanova F, Josephs DH, Correa I, Van Hemelrijck M, Hobbs C, et al. Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. Oncoimmunology 2015;4: e1032492.
46. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211-8.
47. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, et al. Stromal MCP-1 in mammary tumors induces tumor-associated macro-phage infiltration and contributes to tumor progression. Int J Cancer 2009;125:1276-84.
48. Kross KW, Heimdal JH, Olsnes C, Olofson J, Aarstad HJ. Tumour-associated macrophages secrete IL-6and MCP-1 in head and neck squamous cell carcinoma tissue. Acta Otolaryngol 2007;127:532-9.
49. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007;127:2031-41.
50. Teo PZ, Utz PJ, Mollick JA. Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1. Cancer Immunol Immunother 2012;61:2295-309.